Search results for " Progressive"

showing 10 items of 105 documents

No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML

2017

Objective:To examine retrospectively the effects of plasmapheresis (PLEX) on the survival and clinical outcomes of patients with multiple sclerosis (MS) and natalizumab (NTZ)–associated progressive multifocal leukoencephalopathy (PML).Methods:The medical literature was searched for the terms natalizumab and progressive multifocal leukoencephalopathy. A total of 193 international and 34 Italian NTZ-PML cases were included. Clinical outcome was determined by comparing the patients' clinical status at PML diagnosis with status after PML resolution. The effects on survival and clinical outcome of PLEX, sex, age, country, pre-PML Expanded Disability Status Scale score, NTZ infusion number, prior…

OncologyMaleJC virus030204 cardiovascular system & hematologymedicine.disease_causeLeukoencephalopathyDisability Evaluationneurology (clinical); progressive multifocal leukoencephalopathy; reconstitution inflammatory syndrome; multiple-sclerosis0302 clinical medicineNatalizumabImmunologic FactorLeukoencephalopathyRetrospective StudieMultiple SclerosiMedicinePlasmapheresiAdult; Disability Evaluation; Female; Humans; Immunologic Factors; Leukoencephalopathy Progressive Multifocal; Male; Middle Aged; Multiple Sclerosis; Natalizumab; Plasmapheresis; PubMed; Retrospective Studies; Statistics Nonparametric; Treatment OutcomeProgressive multifocal leukoencephalopathyNatalizumabStatisticsLeukoencephalopathy Progressive MultifocalPlasmapheresisMiddle AgedTreatment OutcomeFemaleSettore MED/26 - Neurologiamedicine.drugHumanAdultmedicine.medical_specialtyPubMedMultiple SclerosisProgressive MultifocalStatistics Nonparametric03 medical and health sciencesImmune reconstitution inflammatory syndromeInternal medicineHumansImmunologic FactorsNonparametricprogressive multifocal leukoencephalopathy multiple sclerosis side effectRetrospective StudiesExpanded Disability Status Scalebusiness.industryMultiple sclerosisRetrospective cohort studymedicine.diseaseImmunologyNeurology (clinical)business030217 neurology & neurosurgery
researchProduct

Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors

2021

Background: No uniform criteria for a sensitive identification of the transition from relapsing–remitting multiple sclerosis (MS) to secondary-progressive multiple sclerosis (SPMS) are available. Objective: To compare risk factors of SPMS using two definitions: one based on the neurologist judgment (ND) and an objective data-driven algorithm (DDA). Methods: Relapsing-onset MS patients ( n = 19,318) were extracted from the Italian MS Registry. Risk factors for SPMS and for reaching irreversible Expanded Disability Status Scale (EDSS) 6.0, after SP transition, were estimated using multivariable Cox regression models. Results: SPMS identified by the DDA ( n = 2343, 12.1%) were older, more disa…

Oncologymedicine.medical_specialtyRelapsing-RemittingMultiple sclerosis03 medical and health sciencesMultiple Sclerosis Relapsing-Remitting0302 clinical medicineDisease registryRecurrenceRisk Factorsbig dataInternal medicinemedicineHumansdata-driven algorithmMultiple sclerosi030212 general & internal medicinebig data; data-driven algorithm; disease registry; Multiple sclerosis; prognosis; secondary progressive; Disease Progression; Humans; Recurrence; Risk Factors; Multiple Sclerosis; Multiple Sclerosis Chronic Progressive; Multiple Sclerosis Relapsing-RemittingSecondary progressiveTransition (genetics)business.industryMultiple sclerosisMultiple Sclerosis Chronic Progressivemedicine.diseaseChronic ProgressiveNeurologybig data; data-driven algorithm; disease registry; Multiple sclerosis; prognosis; secondary progressiveDisease Progressiondisease registrysecondary progressiveSettore MED/26 - NeurologiaNeurology (clinical)prognosisbusinessprognosi030217 neurology & neurosurgery
researchProduct

Longitudinal 18F-FDG PET and MRI Reveal Evolving Imaging Pathology That Corresponds to Disease Progression in a Patient With ALS-FTD

2019

Single time point positron emission tomography (PET) studies of patients with amyotrophic lateral sclerosis and frontotemporal dementia (ALS-FTD), have demonstrated hypometabolism or hypermetabolism in certain brain regions. To determine whether longitudinal (at baseline and 20.4 months later) PET and magnetic resonance imaging (MRI) reveal evolving brain imaging pathology corresponding to clinical progression in a patient with ALS-FTD, cerebral glucose metabolic rate, cortical thickness (CT) and cortical area (CA) were obtained and symmetric percent change (SPC) for each calculated. The patient had worsening symptoms and signs of bulbar-onset upper motor neuron-predominant ALS as well as l…

Pathologymedicine.medical_specialtyCase ReportLateralization of brain functionlcsh:RC346-429030218 nuclear medicine & medical imagingPrimary progressive aphasia03 medical and health sciences0302 clinical medicineNeuroimagingAphasiaALS-FTDMedicineAmyotrophic lateral sclerosislcsh:Neurology. Diseases of the nervous systemcortical areamedicine.diagnostic_testbusiness.industryMagnetic resonance imagingcortical thicknessmedicine.diseaseaphasiaPETNeurologyNeurology (clinical)medicine.symptombusinessNeurocognitive030217 neurology & neurosurgeryFrontotemporal dementiaMRIFrontiers in Neurology
researchProduct

Characteristic morphologic manifestation of CADASIL, cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy, in s…

1997

Pathologymedicine.medical_specialtyPhysiologyLeukoencephalopathyCellular and Molecular NeurosciencePhysiology (medical)medicineHumansCADASILMuscle SkeletalSkinbusiness.industryVascular diseaseLeukoencephalopathy Progressive MultifocalSkeletal muscleAnatomyCerebral InfarctionCADASIL SyndromeMiddle Agedmedicine.diseaseIntracranial ArteriosclerosisMicroscopy Electronmedicine.anatomical_structureFemaleNeurology (clinical)ComplicationbusinessMusclenerve
researchProduct

Neuronal and BBB damage induced by sera from patients with secondary progressive multiple sclerosis.

2009

An important component of the pathogenic process of multiple sclerosis (MS) is the blood-brain barrier (BBB) damage. We recently set an in vitro model of BBB, based on a three-cell-type co-culture system, in which rat neurons and astrocytes synergistically induce brain capillary endothelial cells to form a monolayer with permeability properties resembling those of the physiological BBB. Herein we report that the serum from patients with secondary progressive multiple sclerosis (SPMS) has a damaging effect on isolated neurons. This finding suggests that neuronal damaging in MS could be a primary event and not only secondary to myelin damage, as generally assumed. SPMS serum affects the perme…

Pathologymedicine.medical_specialtyProgrammed cell deathBlotting WesternBiologyImmunofluorescenceOccludinModels BiologicalMyelinWestern blotOccludinGeneticsmedicineElectric ImpedanceAnimalsmultiple sclerosis brain cell cultures in vitro models of blood-brain barrier neuronal cell death transendothelial electrical resistanceMicroscopy Phase-ContrastRats WistarCells CulturedNeuronsmedicine.diagnostic_testTight junctionCell DeathMultiple sclerosisMembrane ProteinsGeneral MedicineMultiple Sclerosis Chronic Progressivemedicine.diseaseImmunohistochemistryRatsBlotmedicine.anatomical_structurenervous systemBlood-Brain BarrierAstrocytescardiovascular systemInternational journal of molecular medicine
researchProduct

Depressive Symptom Profiles Predict Specific Neurodegenerative Disease Syndromes in Early Stages

2020

Background: During early stages, patients with neurodegenerative diseases (NDG) often present with depressive symptoms. However, because depression is a heterogeneous disorder, more precise delineation of the specific depressive symptom profiles that arise early in distinct NDG syndromes is necessary to enhance patient diagnosis and care. Methods and Findings: Five-hundred and sixty four participants self-reported their depressive symptoms using the Geriatric Depression Scale (GDS), including 111 healthy older control subjects (NC) and 453 patients diagnosed with one of six NDGs who were at the mild stage of disease (CDR® Dementia Staging Instrument ≤ 1) [186 Alzheimer's disease (AD), 76 be…

PediatricsAgingDiseaseNeurodegenerativeAlzheimer's Diseasefrontotemporal dementialcsh:RC346-429Primary progressive aphasia0302 clinical medicineneurodegenerative diseasehopelessnessworry2.1 Biological and endogenous factorsPsychology030212 general & internal medicineAetiologyDepression (differential diagnoses)Original ResearchdysphoraDepressionAlzheimer'sFrontotemporal Dementia (FTD)Mental HealthNeurologyNeurologicaldepressionGeriatric Depression Scalemedicine.symptomFrontotemporal dementiamedicine.medical_specialtyClinical SciencesDysphoriaProgressive supranuclear palsy7.3 Management and decision making03 medical and health sciencesRare DiseasesClinical ResearchBehavioral and Social SciencemedicineAcquired Cognitive ImpairmentDementialcsh:Neurology. Diseases of the nervous systembusiness.industryNeurosciencesAlzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD)progressive supranuclear palsymedicine.diseaseBrain DisordersGood Health and Well BeingDementiaNeurology (clinical)Management of diseases and conditionsbusiness030217 neurology & neurosurgeryFrontiers in Neurology
researchProduct

Slowly progressive aphasia: a four-year follow-up study

2001

This paper reports the long-term follow-up of GC, a patient with primary progressive aphasia of the fluent type. GC presented at onset with an anomia characterized by sparing of first letter knowledge, that applied mainly to proper names and living categories. No semantic deficits were observed in the first stage of the disease, and MRI showed a left temporal lobe atrophy with a gradient from the pole to the posterior regions, the latter being less involved. We now report the clinical evolution of GC from the 2nd to the 4th year of disease. As the disease progressed, the anomia became more severe and the phenomenon of first letter sparing was no longer detectable. Also semantic knowledge wa…

Pediatricsmedicine.medical_specialtyCognitive NeuroscienceSemantic dementiaExperimental and Cognitive PsychologyNeurological disorderNeuropsychological TestsTemporal lobePrimary progressive aphasiaBehavioral NeuroscienceAtrophyAphasiamedicineHumansSemantic memoryLanguage disorderMiddle Agedmedicine.diseaseSemanticsAphasia Primary ProgressiveDisease ProgressionFemalemedicine.symptomCognition DisordersPsychologyNeuroscienceFollow-Up StudiesNeuropsychologia
researchProduct

Clinical and Instrumental Findings and Disability Progression in Primary Progressive and Progressive Relapsing Multiple Sclerosis: A Comparison Study…

2013

Primary Progressive Multiple Sclerosis Progressive relapsing multiple sclerosisSettore MED/26 - Neurologia
researchProduct

Primary progressive crossed aphasia in dextrals: report of three cases

2013

Primary progressive crossed aphasiaSettore MED/26 - Neurologia
researchProduct

Intravenous gammaglobulin treatment in chronic progressive multiple sclerosis

1998

Progressive multiple sclerosismedicine.medical_specialtyPediatricsNeurologyNeuroscience (all)business.industryGeneral NeuroscienceMultiple sclerosisIntravenous gammaglobulinDermatologyGeneral Medicinemedicine.diseasePsychiatry and Mental healthmedicineChronic progressive multiple sclerosisSettore MED/26 - NeurologiaNeurosurgeryNeurology (clinical)businessNeuroradiology
researchProduct